Delving into the Latest Updates on Dimethylcurcumin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Dimethyl curcumin

+ [2]

Target

AR

Mechanism

AR degraders(Androgen Receptor degraders)

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication

Castration-Resistant Prostatic Cancer

Inactive Indication

Acne VulgarisAlopeciaSpinal Muscular Atrophy+ [1]

Originator Organization

AndroScience Corp.

Active Organization

Nazareth College of Rochester (New York)

Inactive Organization

AndroScience Corp.

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC23H24O6

InChIKeyZMGUKFHHNQMKJI-CIOHCNBKSA-N

CAS Registry52328-98-0

AbstractIn this work, a series of curcumin derivatives (1a–1h, 2a–2g, and 3a–3c) were synthesized for the suppression of castration‐resistant prostate cancer cells. All synthesized compounds were characterized by 1H NMR, 13C NMR, HRMS, and melting point. The in vitro cytotoxicity study shows that compounds 1a, 1e, 1f, 1h, 2g, 3a, and 3c display similar or enhanced cytotoxicity against 22Rv1 and C4‐2 cells as compared to ASC‐J9, other synthesized compounds display reduced cytotoxicity against 22Rv1 and C4‐2 cells as compared to ASC‐J9. Molecular docking simulation was performed to study the binding affinity and probable binding modes of the synthesized compounds with androgen receptor. The results show that all synthesized compounds exhibit higher cdocker interaction energies as compared to ASC‐J9. Compounds 1h, 2g, and 3c not only show strong cytotoxicity against 22Rv1 and C4‐2 cells but also exhibit high binding affinity with androgen receptor. In androgen receptor suppression study, compounds 1f and 2g show similar androgen receptor suppression effect as compared to ASC‐J9 on C4‐2 cells, compound 3c displays significantly enhanced AR suppression effect as compared to ASC‐J9, 1f and 2g. Compounds 1a, 1e, 1f, 1h, 2g, 3a and 3c prepared in this work have significant potential for castration‐resistant prostate cancer therapy.

01 Dec 2023·MethodsX

Validated HPLC method for simultaneous quantitative determination of dimethylcurcumin and resveratrol in pluronic-F127 nanomicelles: Formulation with enhanced anticancer efficacy

Article

Author: Arakkunakorn, Wasiporn ; Basit, Abdul ; Nalinbenjapun, Sirinporn ; Sajomsang, Warayuth ; Pholthien, Watchara ; Ovatlarnporn, Chitchamai ; Sripetthong, Sasikarn

Nano-micelles offer a promising vehicle for the delivery various therapeutically significant biologicals. Development of convenient and efficient chromatographic methods for the quantitative determination of the active pharmaceutical ingredients in such systems is of immense importance. In this study pluronic-F-127 nano-micelles were prepared and loaded with dimethylcurcumin (DMC) and resveratrol (Res). A simple, convenient and effective HPLC method was developed for the quantitative estimation of DMC and Res in the polymeric nano-micelles through a single injection. A reverse-phase ACE® C18 column (250 mm × 4.6 mm) was used with a gradient mobile phase system consisting of 1 % MeOH and 0.1 % H₃PO₄:100 % acetonitrile at 1 mL/min flow rate with UV detection for Res, and fluorescence detector for DMC. The calibration curves generated for both the compounds were found linear with r² values of 1.000 over a concentration range of 2-25 µg/mL with low limit of detection (LOD) values of 0.37 and 0.16 µg/mL for DMC and Res respectively and limit of quantification (LOQ) values of 1.23 and 0.55 µg/mL for DMC and Res respectively. Similarly, accuracy was found in a range of 98.80 -102.47 % for DMC and 100.58-101.77 % for Res. Furthermore, the within-run precisions (%RSD) were 0.073 - 0.444% for DMC and 0.159 - 0.917% for Res, while between-run precisions (%RSD) were 0.344 - 1.47 for DMC and 0.458 - 1.651 for Res. Moreover, the DMC with Res co-loaded nanomicelles showed higher activity against MCF-7 and MDA-MB 231 compared to DMC and Res alone. Overall, this study presented a simple, convenient, precise and accurate method for the quantitative determination of DMC and Res in polymeric nano-micelles which have anticancer potential.•A simple HPLC for the quantitative determination of DMC and Res in nanomicelles having anti-cancer potential.•Non complicate with high degree of recoveries of sample preparation process.•This method can be used to determine a mixture of DMC and Res in pharmaceutical formulation in single injection.

01 Aug 2022·Colloids and Surfaces B: Biointerfaces

Peptide-functionalised magnetic silk nanoparticles produced by a swirl mixer for enhanced anticancer activity of ASC-J9

Article

Author: Hadianamrei, Roja ; Xu, Defeng ; Zhao, Xiubo ; Tomeh, Mhd Anas ; Brown, Stephen

Silk fibroin is an FDA approved biopolymer for clinical applications with great potential in nanomedicine. However, silk-based nanoformulations are still facing several challenges in processing and drug delivery efficiency (such as reproducibility and targetability), especially in cancer therapy. To address these challenges, robust and controllable production methods are required for generating nanocarriers with desired properties. This study aimed to develop a novel method for the production of peptide-functionalized magnetic silk nanoparticles with higher selectivity for cancer cells for targeted delivery of the hydrophobic anticancer agent ASC-J9. A new microfluidic device with a swirl mixer was designed to fabricate magnetic silk nanoparticles (MSNP) with desired size and narrow size distribution. The surface of MSNPs was functionalized with a cationic amphiphilic anticancer peptide, G(IIKK)₃I-NH₂ (G3), to enhance their selectivity towards cancer cells. The G3-MSNPs increased the cellular uptake and anticancer activity of G3 in HCT 116 colorectal cancer cells compared to free G3. Moreover, the G3-MSNPs exhibited considerably higher cellular uptake and cytotoxicity in HCT 116 colorectal cancer cells compared to normal cells (HDFs). Encapsulating ASC-J9 in G3-MSNPs resulted in augmented anticancer activity compared to free ASC-J9 and non-functionalized ASC-J9 loaded MSNPs within its biological half-life. Hence, functionalizing MSNPs with G3 enabled targeted delivery of ASC-J9 to cancer cells and enhanced its anticancer effect. Functionalization of nanoparticles with anticancer peptides could be regarded as a new strategy for targeted delivery and enhanced efficiency of anticancer drugs. Furthermore, the microfluidic device introduced in this paper offers a robust and reproducible method for fabrication of small sized homogenous nanoparticles.

100 Deals associated with Dimethylcurcumin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB06133

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Castration-Resistant Prostatic Cancer	Preclinical	US	Nazareth College of Rochester (New York)	01 Apr 2012
Spinal Muscular Atrophy	Discovery	US	AndroScience Corp.	24 Jan 2011
Wounds and Injuries	Discovery	US	AndroScience Corp.	18 Feb 2009
Alopecia	Discovery	US	AndroScience Corp.	15 Jun 2008
Acne Vulgaris	Discovery	US	AndroScience Corp.	01 Aug 2007

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01289574 (CTgov)	Phase 2	Acne Vulgaris	181	ASC-J9 (Vehicle Control Cream)	axqjczykwa(dykkmvdlof) = jydwsvwyqa wlbtcdwfgo (kpjycabmja, awekdzppex - jvyyonzgjp) View more	-	25 Jul 2014
				ASC-J9 (0.025% ASC-J9 Cream)	axqjczykwa(dykkmvdlof) = sfleorbruu wlbtcdwfgo (kpjycabmja, zxupgtvetp - hiaeowdoek) View more